Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn ' s Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn ' s

Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn ' s disease and ulcerative colitis.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news